EUVIMEDEUVIMED entdecken
Crossref

HPA ‐1a alloimmunization and pregnancy outcome in a Polish screening program: PREVFNAIT

Guz Katarzyna, Uhrynowska Małgorzata, Orzińska Agnieszka iD, Dębska Marzena, Gierszon Agnieszka, Purchla-Szepioła Sylwia, Łopacz Patrycja, Główka Anna, Ahlen Maria Therese iD, Berge Gerd, Coucheron Tina, Dębski Romuald und 4 weitere

Transfusion · 2026

DOI: 10.1111/trf.70080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2026. Verfasst von Guz Katarzyna und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematological and Transfusion Immunology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. Hauptthemen laut MEDLINE: Antigens, Human Platelet, Thrombocytopenia, Neonatal Alloimmune, Isoantibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: the Polish-Norwegian Research Programme operated by the National Center for Research and Development under the Norwegian Financial Mechanism 2009-2014.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fetal/neonatal alloimmune thrombocytopenia (FNAIT) caused by antibodies to human platelet antigen (HPA)‐1a in white HPA‐1a‐negative mothers is the most frequent cause of intracranial hemorrhage (ICH) in otherwise healthy newborns.

Aims

To investigate the natural history of FNAIT and establish a biobank from HPA‐1a‐negative alloimmunized and nonimmunized pregnancies.

Methods

A total of 24,259 pregnant women were recruited to the study during 2013–2017 and 24,236 were screened for HPA‐1a. Anti‐HPA‐1a antibodies were tested by Monoclonal Antibody Immobilization of Platelet Antigens (MAIPA) and some samples (MAIPA‐negative), with Luminex bead‐based immunoassay (PAKLx) if the neonate had thrombocytopenia and/or ICH. HPA‐1 genotyping of fathers, fetuses (from maternal plasma), and newborns was performed. Biological material was stored in biobanks in Norway and Poland.

Results

Among 583/24,236 (2.4%) HPA‐1a‐negative women, samples were obtained from 529, of which 513 were examined during pregnancy. Anti‐HPA‐1a antibodies were detected in 48/529 (9.1%) women; whereof 34/513 (6.6%) during pregnancy, either by prospective MAIPA ( n = 27) or in retrospect by PAKLx in MAIPA‐negatives ( n = 7). FNAIT was diagnosed in 11/34 (32%) neonates from alloimmunized pregnancies: in 6/11 cases by prospective MAIPA and in 5/11 by retrospective PAKLx. There were no neonates with FNAIT‐associated ICH delivered by MAIPA‐positive women, but 3 ICH/severe thrombocytopenia cases were diagnosed by PAKLx. Among nonimmunized HPA‐1a‐negative women, 28 newborns had thrombocytopenia and 2 others had ICH.

Conclusions

Feasibility of HPA‐1 antenatal screening was demonstrated, and a comprehensive biobank was established. The FNAIT detection rate was improved by retrospective diagnostics by PAKLx, including 3 newborns with ICH not identified by prospective MAIPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, Human PlateletThrombocytopenia, Neonatal AlloimmuneIsoantibodiesHumansFemalePregnancyInfant, NewbornPolandPregnancy OutcomeAdultIntegrin beta3

Stichwörter der Autor:innen

antibodies to human platelet antigen (HPA)‐1afetal and neonatal alloimmune thrombocytopenia (FNAIT)inctracranial hemorrhage (ICH)

Substanzen

Antigens, Human PlateletIsoantibodiesITGB3 protein, humanIntegrin beta3

Autor:innen und Institutionen

  • Department of Hematological and Transfusion Immunology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Department of Obstetrics and Perinatology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.
  • Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
  • Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway.
  • Debski Clinic Medical Center, Warsaw, Poland.
  • Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.

ORCID-Profile: Orzińska Agnieszka, Ahlen Maria Therese

Förderung

  • the Polish-Norwegian Research Programme operated by the National Center for Research and Development under the Norwegian Financial Mechanism 2009-2014

Zitieren

APA

Katarzyna, G., Małgorzata, U., Agnieszka, O., Marzena, D., Agnieszka, G., Sylwia, P. S., Patrycja, Ł., Anna, G., Therese, A. M., Gerd, B., Tina, C., Romuald, D., Listau, B. E., Heidi, T., Anne, H., & Ewa, B. (2026). HPA ‐1a alloimmunization and pregnancy outcome in a Polish screening program: PREVFNAIT. Transfusion. https://doi.org/10.1111/trf.70080

Vancouver

Katarzyna G, Małgorzata U, Agnieszka O, Marzena D, Agnieszka G, Sylwia PS, et al. HPA ‐1a alloimmunization and pregnancy outcome in a Polish screening program: PREVFNAIT. Transfusion. 2026. doi:10.1111/trf.70080

BibTeX
@article{Katarzyna2026,
  author = {Katarzyna, Guz and Małgorzata, Uhrynowska and Agnieszka, Orzińska and Marzena, Dębska and Agnieszka, Gierszon and Sylwia, Purchla-Szepioła and Patrycja, Łopacz and Anna, Główka and Therese, Ahlen Maria and Gerd, Berge and Tina, Coucheron and Romuald, Dębski and Listau, Bertelsen Eirin and Heidi, Tiller and Anne, Husebekk and Ewa, Brojer},
  title = {HPA ‐1a alloimmunization and pregnancy outcome in a Polish screening program: PREVFNAIT},
  journal = {Transfusion},
  year = {2026},
  doi = {10.1111/trf.70080}
}
Kostenlos starten →